In vivo experiments using two different liver fibrosis mouse models showed a weakening effect on liver fibrosis, and we reported that along with YAP-CTGF, HSD17B13, which is involved in retinoic acid metabolism [108,109] and nonalcoholic fatty liver disease [110], was associated with this effect [49]. This evidence concerns the gene CCN2 and Hepatic fibrosis.